-
Innovation Ranking
Innovation Ranking – Polaris Inc
Polaris Inc (Polaris), formerly Polaris Industries Inc is a manufacturer of automobiles. The company specializes in designing, engineering and producing off-road vehicles (ORV), which include all-terrain vehicles (ATV) and side-by-side vehicles for recreational and utility use, motorcycles, small vehicles (SV) and snowmobiles. The product portfolio of the company includes side by side vehicles, all-terrain vehicles, snowmobiles, commercial utility vehicles and personal quadricycles. The company also provides related replacement parts, garments and accessories (PG&A). Its services include financing, insurance services and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-319 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-319 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-319 in Follicular Lymphoma Drug Details: ABBV-319 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Metastatic Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Metastatic Prostate Cancer Drug Details: ALG.APV-527 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Non-Small Cell Lung Cancer Drug Details: MHB-088C...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Glioblastoma Multiforme (GBM) Drug Details: Pegargiminase (ADI-PEG 20)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Gliosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Gliosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Gliosarcoma Drug Details: Pegargiminase (ADI-PEG 20) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Pegargiminase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Pegargiminase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Leiomyosarcoma Drug Details: Pegargiminase (ADI-PEG 20) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegargiminase in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegargiminase in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegargiminase in Non-Small Cell Lung Cancer Drug Details: Pegargiminase...